3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Carcinoma, Transitional Cell
14
Urinary Bladder Neoplasms
11
Breast Neoplasms
11
Neoplasm Metastasis
10
Carcinoma, Renal Cell
8
Carcinoma, Merkel Cell
8
Neoplasms
7
Colorectal Neoplasms
7
Head and Neck Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Neuroendocrine Tumors
4
Leukemia, Myeloid, Acute
4
Urethral Neoplasms
3
Ureteral Neoplasms
3
Skin Neoplasms
3
Prostatic Neoplasms
3
Glioblastoma
3
Endometrial Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Neuroendocrine
3
Carcinoma, Hepatocellular
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Penile Neoplasms
2
Pancreatic Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasm, Residual
2
Mesothelioma, Malignant
2
Interventions
Cyclophosphamide
72
fludarabine phosphate
64
Peripheral Blood Stem Cell Transplantation
64
Busulfan
50
Cyclosporine
48
Mycophenolic Acid
45
Tacrolimus
41
Antilymphocyte Serum
41
Radiotherapy
37
Whole-Body Irradiation
33
Methotrexate
33
Filgrastim
33
Imatinib Mesylate
27
Methylprednisolone
25
Cord Blood Stem Cell Transplantation
24
Melphalan
22
Dasatinib
16
sargramostim
15
Etoposide
15
nilotinib
14
Cytarabine
14
Interferon-alpha
13
Therapeutics
11
Flow Cytometry
11
Cyclosporins
11
Thiotepa
9
Sirolimus
9
Alemtuzumab
9
Polymerase Chain Reaction
8
Psychiatric Rehabilitation
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, Myeloid, Chronic-Phase
×
avelumab
×
Clear all
NCT02767063
2020-08-07
ACTIW
Versailles Hospital
Phase 1/2
Unknown
100 enrolled